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Objectives: Modulation of sputum rheology represents an important therapeutic
target in chronic inﬂammatory lung disease such as cystic ﬁbrosis (CF). The
novel alginate oligomer (OligoG) modulates pseudomonal bioﬁlms and increases
susceptibility of multi-drug resistant bacteria to antibiotics and has previously been
shown to modify rheology of mucin/alginate gels, mucin/DNA gels and sputum
from a CF patient. This study tested the ability of OligoG to modify the rheological
properties of CF sputum.
Methods: The effect of OligoG on the viscoelastic properties of sputum samples
from cystic ﬁbrosis patients (n = 23) and in a longitudinal study (10 weeks) was
studied using shear and extensional rheology. Samples were subjected to 7 treatment
modalities:
i. distilled water control;
ii. 7% saline;
iii. 100 nM dornase alpha (Pulmozyme®: Pz);
iv. 0.2% OligoG;
v. 2% OligoG;
vi. 100 nM Pz and 0.2% OligoG;
vii. 100 nM Pz and 2% OligoG.
An oscillatory frequency sweep was conducted and the values of storage and loss
modulus (G’, G”) analysed to detect changes in viscoelasticity. Extensional rheology
was employed to detect changes in 2% OligoG treated sputum, in comparison to
the control.
Conclusion: OligoG signiﬁcantly decreased the storage and loss modulus of
sputum (P< 0.0001), as well as the extensional viscosity. OligoG also signiﬁcantly
potentiated the effect of Pz (P< 0.01). These studies show that use of inhaled
oligosaccharide nanomedicines such as OligoG may provide a novel, well-tolerated
therapeutic approach in the treatment of impaired lung clearance and chronic
bacterial colonization in chronic inﬂammatory lung diseases.
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Objectives: Despite recent advances, clinicians are still confronted with low success
rates when treating bioﬁlm based infections. In CF patients, pulmonary bioﬁlm
infections are an important cause of morbidity and mortality. Recently, increased
sensitivity of bioﬁlms towards nanoparticle encapsulated antibiotics was shown in
vitro. When applying this concept to pulmonary bioﬁlms, two aspects need to be
evaluated for the development of a suitable nanocarrier. Firstly, the particles need
to be mobile in the highly visco-elastic mucus in order to reach the bioﬁlms.
Secondly, the nanoparticles need to be able to penetrate into the bioﬁlm for a
maximal antimicrobial effect.
Methods: In earlier work, transport studies based on Single Particle Tracking
(SPT) microscopy of differently functionalized polystyrene nanoparticles showed
that PEGylation is essential for transport in CF sputum and bioﬁlms. Currently,
confocal microscopy and ﬂuorescence recovery after photobleaching are used to
gain insight in the nanoparticle size cutoff for efﬁcient transport into clusters of
B. multivorans bioﬁlms using PEGylated micelles (25 nm), PEGylated silica (25,
45, 75 nm) and PEGylated polystyrene (100, 200 nm) nanoparticles.
Conclusion: The micelles, silica and 100 nm polystyrene nanoparticles were ob-
served to diffuse well inside the clusters. Although further investigation is required,
ﬁrst experiments show that 200 nm nanoparticles penetrate less, suggesting a cut-
off size of about 100 nm. Combining different ﬂuorescence microscopy techniques
can thus aid in the rational design of nanocarriers for drug delivery with optimal
transport properties in mucus and bioﬁlms.
